Antacids are a group of medications that helps in neutralize the content of acid reflux in the stomach. It provides fast relief of heartburn, one of the main symptoms of gastroesophageal reflux digestion and other symptoms are nausea, bloating or belching. Antacids include magnesium carbonate, aluminium hydroxide, and magnesium trisilicate. Some people have reported allergic reactions to antacids. Antacids incorporate magnesium carbonate, aluminium hydroxide, and magnesium trisilicate. A few people have announced unfavourably susceptible responses to antacids.
Antacids Market value was worth USD 16.0 billion in 2019 and estimated to be growing at a CAGR of 4.24%, to reach USD 19.7 billion by 2024.
Drivers and Restraints:
The growing trend toward self-medication is increasing the demand for over-the-counter digestive products for the treatment of gastrointestinal disorders. Antacids are used to neutralize acidity and should therefore cause a dramatic increase in demand. According to a study conducted by the American Gastroenterological Association and published in the International Functional Foundation in February 2017, about one-third of the US population. Suffering from GERD. Market restraints include some side effects such as constipation, laxative effect and allergic reactions. In addition, people suffering from certain medical conditions are prone to adverse effects that worsen their state of health because people with heart disease may have problems due to the high amount of sodium present in antacids.
Market Segmentation:
The market is segmented by drug class, by Formulation type, by Distribution channel and by application technique. By Drug class type the market is categorized into Proton Pump Inhibitors, H2 Antagonist, Acid neutralizers, and Pro-motility agents. Amongst all Proton pump inhibitors segment led the market in 2017 and the trend is anticipated to continue in forecast period. However acid neutralizers segment emerge as significant segment because of their extensive use in occasional heartburn and their availability range. By Formulation type the market is segmented into tablet, liquid and power. Tablet is the leading segment in 2017 and is anticipated to be the highest growing segment due to convenience in administration, low pricing and largely available. By distribution channel the market is segmented into Hospital Pharmacies and retail pharmacies and other. Other segments include online pharmacies and drug store which led the market segment. Rising adoption e- commerce and increase in number of online stores are boosting the growth of the market.
Geographical Segmentation:
By geography the market is segmented into Latin America, Asia Pacific, Europe, North America, and Middle East and Africa. North America held the leading share in the overall market due to factors like increasing number of gastro oesophageal diseases and growing geriatric population. Asia pacific stood second in contributing the market share. China and India are the key dominant regions due to improvements and healthcare services.
Key Players:
The main players in the market are GlaxoSmithKline plc, Abbott Laboratories and Pfizer, Inc. Sun Pharma has launched an Ayurvedic digestive remedy called Pepmelt to compete with popular antacids such as ENO (Consumer Health), Digene (Abbott India) and Pudin Hara( Dabur). And Gelusil (Pfizer)
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Drug Class
5.1.1 Introduction
5.1.2 Proton Pump Inhibitors
5.1.3 H2 Antagonist
5.1.4 Pro-motility agents
5.1.5 Acid Neutralizers
5.1.6 Y-o-Y Growth Analysis, By Drug Class
5.1.7 Market Attractiveness Analysis, Drug Class
5.1.8 Market Share Analysis, By Drug Class
5.2 Formulation Type
5.2.1 Introduction
5.2.2 Tablet
5.2.3 Liquid
5.2.4 Powder
5.2.5 Y-o-Y Growth Analysis, By Formulation Type
5.2.6 Market Attractiveness Analysis, By Formulation Type
5.2.7 Market Share Analysis, By Formulation Type
5.3 Distribution Channel
5.3.1 Introduction
5.3.2 Hospital Pharmacies
5.3.3 Retail pharmacies
5.3.4 Other
5.3.5 Y-o-Y Growth Analysis, By Distribution Channel
5.3.6 Market Attractiveness Analysis, By Distribution Channel
5.3.7 Market Share Analysis, By Distribution Channel
5.4 Disease Indications 5.4.1 Introduction
5.4.2 Cancer
5.4.3 CardiovascularDisorders
5.4.4 Neurological Disorders
5.4.5 Immunological Disorders
5.4.6 Other Diseases
5.4.7 Y-o-Y Growth Analysis, By Disease Indications
5.4.8 Market Attractiveness Analysis, By Disease Indications
5.4.9 Market Share Analysis, By Disease Indications
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Drug Class
6.1.3.3 By Formulation Type
6.1.3.4 By Distribution Channel
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Drug Class
6.1.4.3 By Formulation Type
6.1.4.4 By Distribution Channel
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Drug Class
6.1.5.3 By Formulation Type
6.1.5.4 By Distribution Channel
6.2 North America
6.1.1 Introduction
6.1.2 United States
6.1.3 Canada
6.3 Europe
6.2.1 Introduction
6.2.2 U.K
6.2.3 Spain
6.2.4 Germany
6.2.5 Italy
6.2.6 France
6.4 Asia-Pacific
6.3.1 Introduction
6.3.2 China
6.3.3 India
6.3.4 Japan
6.3.5 Australia
6.3.6 South Korea
6.5 Latin America
6.4.1 Introduction
6.4.2 Brazil
6.4.3 Argentina
6.4.4 Mexico
6.4.5 Rest of Latin America
6.6 Middle East & Africa
6.5.1 Introduction
6.5.2 Middle-East
6.5.3 Africa
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Glaxo Smith
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Abbott Laboratories
8.3 Pfizer Inc
8.4 Sun Pharmaceuticals
8.5 Consumer Health
8.6 Dabur
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
